Prescribers give thumbs up to Biotie/Lundbeck's Selincro
This article was originally published in Scrip
Executive Summary
Selincro (nalmefene), the alcohol-dependence drug licensed to Lundbeck from Finnish firm Biotie, is going down well with prescribers, says Andreas Eggert, Lundbeck's senior vice-president of global product strategy & portfolio development. as the company prepares for its imminent launch in in the first markets where it has won reimbursement: the Netherlands and Denmark .